CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Advertisement

Nipro April 2026
Discovery Toxicology Services
Drug Discovery and Development V5 I4

Discovery Toxicology Services

Toxicology the study of poisons, determines whether a drug can be used on humans. Almost 30% of clinical trial attritions are attributed to the toxicological profile...
Continue Reading →
Improving and Refining Models of Acquired Resistance for Efficient Oncology Drug Discovery
Drug Discovery and Development V5 I4

Improving and Refining Models of Acquired Resistance for Efficient Oncology Drug Discovery

Conventional chemotherapy has been, for many years, the prevalent type of anti-cancer treatment. However its broad-based mechanisms, DNA alkylating agents, usually l...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026